Brainstorm Cell Therapeutics Inc. (BCLI) Financial Ratios
25 years of historical data (2001–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
N/A
—
5yr avg: 7.52
30Y Low0.1·High158.7
ROE
↓
N/A
—
5yr avg: -193.3%
30Y Low-297%·High-41%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
BCLI Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Brainstorm Cell Therapeutics Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $10M | $5M | $12M | $16M | $60M | $145M | $153M | $109M | $74M | $74M | $47M |
| Enterprise Value | $10M | $5M | $13M | $16M | $63M | $132M | $123M | $111M | $73M | $72M | $47M |
| P/E Ratio → | -0.78 | — | 1.04 | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | — | — | — | — | — | 7.52 | 4.32 | — | 14.74 | 12.65 | 4.79 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
BCLI EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
BCLI Profitability
Margins and return-on-capital ratios measuring operating efficiency
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | 200.0% | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | 6284.4% | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | 6353.3% | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | -297.4% | -89.2% | -273.7% | — | -256.0% | -62.8% | -41.5% |
| ROA | -809.3% | -809.3% | 384.9% | -271.6% | -128.7% | -60.7% | -110.1% | -261.8% | -123.2% | -44.6% | -35.8% |
| ROIC | — | — | — | — | -634.2% | -353.4% | — | — | -282.4% | -58.8% | -33.1% |
| ROCE | — | — | — | — | -219.6% | -77.9% | -219.2% | — | -258.1% | -63.4% | -42.3% |
BCLI Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $179000 ($208000 total debt minus $29000 cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | 0.26 | 0.20 | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | — | -0.71 | -0.86 | — | -0.19 | -0.42 | -0.06 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -149.95 | — | — | — | — | — | — | — | — |
BCLI Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.03x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 0.24x to 0.03x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.03 | 0.03 | 0.04 | 0.24 | 0.35 | 3.69 | 3.85 | 0.19 | 1.65 | 1.74 | 12.09 |
| Quick Ratio | 0.03 | 0.03 | 0.04 | 0.24 | 0.35 | 3.69 | 3.85 | 0.19 | 1.65 | 1.74 | 12.09 |
| Cash Ratio | 0.00 | 0.00 | 0.02 | 0.17 | 0.34 | 3.50 | 3.73 | 0.03 | 1.14 | 1.40 | 11.56 |
| Asset Turnover | — | — | — | — | — | — | — | -0.06 | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
BCLI Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Brainstorm Cell Therapeutics Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 96.5% | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $9M | $5M | $4M | $2M | $2M | $2M | $2M | $1M | $1M | $1M |
Peer Comparison
Compare BCLI with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 BCLIYou | $10M | -0.8 | — | — | — | — | — | — | — |
 CLLS | $299M | -4.4 | — | — | 86.6% | -45.3% | -65.3% | -23.5% | — |
 FATE | $244M | -1.8 | — | — | -94.1% | -2222.4% | -51.8% | -36.5% | — |
 AGEN | $125M | -882.4 | — | — | 29.6% | -18.0% | — | — | — |
 NKTR | $1B | -6.3 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 SNGX | $4M | -0.2 | — | — | — | — | -235.5% | — | — |
 BIIB | $29B | 22.3 | 11.7 | 14.2 | 70.5% | 19.1% | 7.4% | 6.5% | 2.5 |
 IONS | $12B | -31.1 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 PRTA | $468M | -2.0 | — | — | 61.8% | -1905.8% | -63.6% | -2099.8% | — |
 ARVN | $495M | -6.0 | — | — | 98.0% | -43.8% | -16.2% | -22.4% | — |
 ALNY | $37B | 119.4 | 65.9 | 79.7 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 24 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
BCLI — Frequently Asked Questions
Quick answers to the most common questions about buying BCLI stock.
What is Brainstorm Cell Therapeutics Inc.'s P/E ratio?
Brainstorm Cell Therapeutics Inc.'s current P/E ratio is -0.8x. The historical average is 1.0x.
Is BCLI stock overvalued?
Based on historical data, Brainstorm Cell Therapeutics Inc. is trading at a P/E of -0.8x. Compare with industry peers and growth rates for a complete picture.